19-May-2003
NEL HOME, Newsletter
AIM & SCOPE
BOARD OF EDITORS
INSTRUCTIONS
CONTENTS Vol.24 Nos.1/2 Feb-Apr 2003
VOL.22, 2001
VOL.21, 2000
VOL.20, 1999
VOL.19, 1998
VOL.18, 1997
HUMAN ETHOLOGY
PREVIEW coming
PRESS ROOM
CONTACT
SUBSCRIBE order

NEUROENDOCRINOLOGY LETTERS
including Psychoneuroimmunology, Neuropsychopharmacology,
Reproductive Medicine, Chronobiology
and Human Ethology, ISSN 0172–780X

NEL Vol.24 No.1/2, Feb-Apr 2003

ORIGINAL ARTICLE

Methoxytryptamine effect on cisplatin-induced anemia

2003; 24:83–85
pii: NEL241203A13
PMID: 12743539

[Read pdf 121kb]

Buy PDF article
Check Out

 

Reduction of cisplatin-induced anemia by the pineal indole 5-methoxytryptamine in metastatic lung cancer patients

Paolo Lissoni, Fabio Malugani, Roberta Bukovec, Veronica Bordin, Maristella Perego, Susan Mengo, Antonio Ardizzoia & Gabriele Tancini

1. Department of Internal Medicine, Regional General Hospital “Casa Sollievo della Sofferenza”, Cappuccini Av., 71013 S.Giovanni Rotondo (FG), ITALY.
2. Center of Chronobiology, Department of Internal Medicine, University of Florence, Pieraccini Av., 50100 Florence (FI), ITALY.

Submitted: July 29, 2002 Accepted: August 7, 2002

Key words:
chemotherapy-induced anemia, cisplatin, methoxytryptamine, pineal indoles

 

Abstract

OBJECTIVE: It has been demonstrated that the hematopoiesis is under a neuroendocrine control, namely mediated by the pineal gland. The pineal indole melatonin (MLT) has appeared to exert thrombopoietic and lymphopoietic activity, whereas it has no relevant effect on red cell differentiation. The present study was performed to evaluate the influence of another pineal indole, the 5-methoxytryptamine (5-MTT) on red cell line and hemoglobin production.

MATERIALS & METHODS: The study was carried out in metastatic lung cancer patients who underwent a chemotherapeutic combination containing cisplatin, which is known to induce anemia. The study included 20 patients treated with cisplatin plus etoposide, who were randomized to receive chemotherapy alone or chemotherapy plus 5-MTT (1 mg/day orally at noon every day).

RESULTS: Hemoglobin mean blood concentrations significantly decreased in both groups of patients. However, the decrease in hemoglobin levels observed in patients treated with chemotherapy alone was significantly higher with respect to that observed in patients concomitantly treated with 5-MTT. Moreover, the percent of patients who had no progressive disease on treatment was significantly higher in the group treated with chemotherapy plus 5-MTT.

CONCLUSIONS: Even though the low number of patients does not allow us to draw define conclusions, these preliminary results would show that the concomitant administration of 5-MTT may reduce cisplatin-induced anemia in cancer patients, by suggesting a hematopoietic activity of 5-MTT on red cell line differentiation and hemoglobin production. Moreover, the study would suggest that 5-MTT, as well as previously demonstrated for MLT, may also enhance the cytotoxic activity of cancer chemotherapy.

__________________________________________________________
Copyright © Neuroendocrinology Letters 2003
Society of Integrated Sciences
All rights reserved. No part may be reproduced, stored in a retrieval system, or transmitted in any form or by any means, electronic, mechanical, photocopying, recording, or ortherwise, without prior written permission from the Editor-in-Chief.
The latest statistics from the www.nel.edu